Aevitas Wealth Management, Inc. Intellia Therapeutics, Inc. Transaction History

Aevitas Wealth Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 25, 2022	SELL	$58.27 - $118.99 $107,799 - $220,131	-1,850 Closed	0 $0
Q4 2021 Jan 19, 2022	SELL	$100.76 - $138.36 $151,140 - $207,540	-1,500 Reduced 44.78%	1,850 $219,000
Q3 2021 Nov 01, 2021	SELL	$132.37 - $176.78 $52,948 - $70,712	-400 Reduced 10.67%	3,350 $449,000
Q4 2020 Jan 19, 2021	BUY	$18.83 - $63.53 $70,612 - $238,237	3,750 New	3,750 $204,000
Q2 2019 Jul 26, 2019	SELL	$13.88 - $18.41 $9,716 - $12,887	-700 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$17.39 - $31.12 $12,173 - $21,784	700	700 $13,000

336

96.1M

1.06M

863K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $925M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Aevitas Wealth Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Aevitas Wealth Management, Inc. with notifications on news.